Quality of Life of Patients With a History of Drug Allergy in Thailand

NCT ID: NCT01666470

Last Updated: 2019-02-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

306 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-08-31

Study Completion Date

2017-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Quality of life of patients with a history of drug allergy in Thailand will be studied.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Thai patients with a history of drug allergy will be evaluated for their quality of life based on drug hypersensitivity quality of life questionnaire (DrHy-Q; Thai version) and The World Health Organization Quality of Life instrument (WHOQOL-BREF-THAI)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Quality of Life

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Drug allergy patients

Patients with a history of drug allergy in Thailand

Questionnaires

Intervention Type OTHER

DrHy-Q (Thai version) and WHOQOL-BREF-THAI will be asked

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaires

DrHy-Q (Thai version) and WHOQOL-BREF-THAI will be asked

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a history of drug allergy
* At least 18 years of age

Exclusion Criteria

* Not be able to understand Thai language
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mahidol University

OTHER

Sponsor Role collaborator

Chulalongkorn University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jettanong Klaewsongkram

Head of Division of Allergy and Clinical Immunology, Department of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jettanong Klaewsongkram, MD

Role: PRINCIPAL_INVESTIGATOR

Chulalongkorn University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Medicine, Chulalongkorn University

Bangkok, , Thailand

Site Status

Faculty of Medicine, Ramathibodi Hospital, Mahidol University

Bangkok, , Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Related Links

Access external resources that provide additional context or updates about the study.

https://www.ncbi.nlm.nih.gov/pubmed/30346532

Reliability and validity of the Thai Drug Hypersensitivity Quality of Life Questionnaire: a multi-center study

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Chula-ARC 001/12

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Antiplatelet Therapy in Chronic Urticaria
NCT06268470 ACTIVE_NOT_RECRUITING PHASE2
Early Intervention in Allergic Patients
NCT05040828 COMPLETED PHASE4